Back to Search Start Over

CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.

Authors :
Veldman J
Rodrigues Plaça J
Chong L
Terpstra MM
Mastik M
van Kempen LC
Kok K
Aoki T
Steidl C
van den Berg A
Visser L
Diepstra A
Source :
Oncoimmunology [Oncoimmunology] 2022 Jan 27; Vol. 11 (1), pp. 2033433. Date of Electronic Publication: 2022 Jan 27 (Print Publication: 2022).
Publication Year :
2022

Abstract

In classical Hodgkin lymphoma (cHL), the highly abundant CD4+ T cells in the vicinity of tumor cells are considered essential for tumor cell survival, but are ill-defined. Although they are activated, they consistently lack expression of activation marker CD26. In this study, we compared sorted CD4+CD26- and CD4+CD26+ T cells from cHL lymph node cell suspensions by RNA sequencing and T cell receptor variable gene segment usage analysis. This revealed that although CD4+CD26- T cells are antigen experienced, they have not clonally expanded. This may well be explained by the expression of exhaustion associated transcription factors TOX and TOX2 , immune checkpoints PDCD1 and CD200 , and chemokine CXCL13 , which were amongst the 100 significantly enriched genes in comparison with the CD4+CD26+ T cells. Findings were validated in single-cell RNA sequencing data from an independent cohort. Interestingly, immunohistochemistry revealed predominant and high frequency of staining for TOX and TOX2 in the T cells attached to the tumor cells. In conclusion, the dominant CD4+CD26- T cell population in cHL is antigen experienced, polyclonal, and exhausted. This population is likely a main contributor to the very high response rates to immune checkpoint inhibitors in cHL.<br />Competing Interests: A.D. receives research funding from Millenium/Takeda. C.S. is an advisory board member for Curis Inc., AbbVie, Seattle Genetics, and Roche, reports receiving commercial research grants from Bristol-Myers Squibb and Trillium Therapeutics, and remuneration from Bayer and Juno Therapeutics. No potential conflicts of interest were disclosed by the other authors.<br /> (© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.)

Details

Language :
English
ISSN :
2162-402X
Volume :
11
Issue :
1
Database :
MEDLINE
Journal :
Oncoimmunology
Publication Type :
Academic Journal
Accession number :
35111387
Full Text :
https://doi.org/10.1080/2162402X.2022.2033433